The high expression and accessible nature of the IGFBP7 target in GBM vessels, combined with virtually non-existent expression in normal vessels, in combination with demonstrated versatility and good in vivo targeting characteristics of anti-IGFBP7 sdAb, indicate that linking of this antibody to the appropriate optical, PET or MRI contrast agents could enable in vivo imaging assessment of the degree of angiogenesis in gliomas. The gene discussed is IGFBP7; the disease is glioblastoma.